---
$id: https://graph.org.ai/products/commodity/51131721
$type: Product
source: UNSPSC
code: "51131721"
title: "Bepafant"
class: "51131700"
classTitle: "Thrombolytic drugs and platelet aggregation inhibitors"
family: "51130000"
familyTitle: "Hematolic drugs"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Bepafant

**UNSPSC Code**: 51131721
**Class**: [Thrombolytic drugs and platelet aggregation inhibitors](Thrombolytic drugs and platelet aggregation inhibitors.mdx)
**Family**: [Hematolic drugs](../Hematolic drugs.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes an antiplatelet agent with the molecular formula C23H22ClN5O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CKS724B66O, chemically known as 4-((6-(o-chlorophenyl)-8,9-dihydro-1-methyl-4h,7h-cyclopenta(4,5)thieno(3,2-f)-s-triazolo(4,3-a)(1,4)diazepin-8-yl)carbonyl)morpholine but generally known as bepafant, which bears US NIH Compound Identifier 65923. European Medicines Agency schedules Bepafant in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05774MIG. The term BEPAFANT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). Most nations schedule bepafant under HS 29349990 and SITC 51579. As of Q4 2014, BEPAFANT remains the US FDA Preferred Term for this commodity. Bepafant bears US NLM identifiers UMLS ID C0378528 and NCI Concept Code C77947. SMILES: CLC1C(C2=NCC3N(C4SC5CC(CC5C24)C(=O)N2CCOCC2)C(NN3)C)CCCC1.

